ALZHEIMER'S DISEASE

Hopes that will not be disappointed to prevent Alzheimer's disease (Debled G.)

• The clinical studies carried out to date are remarkable. They highlight the important impact of testosterone on Alzheimer's disease (1-2-3-4-5).

• There are however recent publications by eminent researchers who question the effectiveness of androgens in Alzheimer's disease (6-7).

• The role of tetosterone and androgens to treat and prevent Alzheimer's disease would require a more detailed approach.

• It seems useful to draw attention to the fact that clinical studies are often based on the study of the level of testosterone in the blood, which does not allow a precise idea of the androgen metabolism. Future studies could draw inspiration from this because evaluation of the daily production of androgens should be considered.

• A blood testosterone level of 1500 ng / 100 ml may correspond to a pathology (in man). On the other hand, a level of 350ng / 100 ml (in man) can correspond to a non pathological metabolism not requiring hormonal supplementation.

• Clinical studies are often done in a double-blind manner, which gives a general idea of ​​the results by eliminating the subjective factors. They are very useful in guiding research.
  We would like to draw attention to the hormonal uniqueness of each person with Alzheimer's disease. To understand this hormonal singularity, a detailed study of the androgenic metabolism should be carried out in each patient.

• The singular study of androgens in each person with Alzheimer's disease makes it possible to prescribe a precise treatment (testosterone is not the only androgen available) and well dosed.
  The administration of a standard dose of testosterone is often proposed to treat each patient. The singularity of the biological results for each patient implies a singular treatment by the androgens or a possible singular contraindication to this treatment. Failing this, a single standard dose of testosterone can lead to undesirable effects (7).

• The disappointments (6) and undesirable effects (7) caused by testosterone could be avoided by a better knowledge of androgen therapy. Considering a standard dose of testosterone for each patient is unreasonable (diabetes or thyroid insufficiency are not treated with a standard dose of insulin or a standard dose of thyroxine).

• To resolve apparent contradictions in testosterone therapy, clinical studies and future treatments should be based on a detailed analysis of androgen metabolism in people with Alzheimer's disease. They will probably better understand the treatment and hormonal prevention of this disease.

• Regularization of androgen metabolism should occur at the onset of early symptoms of Alzheimer's disease and further upstream as soon as the first symptoms of menopausal disease appear.